21076 ⎘
Medicinal preparations containing antigens or antibodies; Protozoa antigens Hemosporidia antigens, e.g. Plasmodium antigens
Sub-classes:COMPOSITIONS FOR DELIVERY OF PLASMODIUM CSP ANTIGENS AND RELATED METHODS
#2MALARIA IMMUNOGEN AND METHODS OF USING SAME
#3Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
#4AUTOMATED HEART VALVE MANUFACTURING
#5LAYER-BY-LAYER DELIVERY OF ACTIVE AGENTS
#6INJECTABLE HYDROGELS FOR CONTROLLED RELEASE OF IMMUNOMODULATORY COMPOUNDS
#7Adenoviral Vectors Comprising Partial Deletions of E3
#8IMMUNOGENICITY OF PLASMODIUM VIVAX CIRCUMSPOROZOITE PROTEIN NANOPARTICLE VACCINES
#9USE OF NON-INFORMATIONALAMINO ACID CHAINS TO MODIFY THE SOLUBILITY PROPERTIES OF PEPTIDES
#10MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY
#11ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM
#12INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO
#13PFCSP-BASED IMMUNOGENS AND RELATED COMPOSITION AND METHODS
#14METHODS AND COMPOSITIONS RELATING TO IMMUNIZATION OF IMMUNE DISTINCT PATIENTS
#15AUTOMATED HEART VALVE MANUFACTURING
#16SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS
#17NANOPARTICLE PLATFORM FOR ANTIBODY AND VACCINE DELIVERY
#18SAPONIN-BASED ADJUVANTS AND VACCINES
#19USE OF TRIMANGANESE TETRAOXIDE PARTICLES IN PREPARATION OF VACCINE ADJUVANT
#20IMMUNOSTIMULATORY COMPOSITIONS
#21COMPOSITIONS AND METHODS FOR REDUCING PARASITIC INFECTIONS
#22MALARIA VACCINE FORMULATIONS
#23METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING MALARIA
#24Anti-PfRH5 Antibodies and Antigen-Binding Fragments Thereof
#25NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE
#26SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
#27COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO TREAT OR PREVENT MALARIA
#28COMPOSITIONS INCORPORATING A GENETICALLY ATTENUATED PLASMODIUM WITH MODIFIED LIVER STAGE NUCLEAR PROTEIN (LINUP) AND RELATED METHODS
#29TROPICAL DISEASE VACCINES
#30POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE
#31MINERAL-COATED SUBSTRATES FOR STABILIZATION OF RNA-BASED THERAPEUTIC COMPOSITIONS
#32SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
#33Universal mRNA Antimalarial Vaccine
#34ANTI-PARASITIC IMMUNOLOGICAL COMPOSITIONS
#35Immunogenic compositions, antigen screening methods, and methods of generating immune responses
#36MODIFIED VIRUS-LIKE PARTICLES OF BACTERIOPHAGE AP205
#37IMMUNOGENIC COMPOSITIONS
#38Infectious plasmodium sporozoites grown in vitro
#39CHEMOVACCINATION AGAINST PLASMODIUM INFECTION WITH SELECTIVE PLASMEPSIN X INHIBITORS
#40Automated heart valve manufacturing
#41Vaccines and Antibodies for the Treatment and Prevention of Microbial Infections
#42ADMINISTRATION REGIMENS FOR MICRONEEDLE PATCH DEVICES FOR DELIVERY OF IMMUNOGENIC COMPOSITIONS
#43METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA
#44SYNTHETIC PLASMODIUM ANTIGENS, COMPOSITIONS, AND USES THEREOF
#45PD-1 Peptide Inhibitors
#46CIRCUMSPOROZOITE PROTEINS WITH INCREASED EXPRESSION IN MAMMALIAN CELLS
#47SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS
#48NOVEL VAR2CSA IMMUNOGENS AND METHODS OF USE THEREOF
#49PD-1 Peptide Inhibitors
#50COMPOSITIONS AND METHODS FOR TARGETING PLASMODIUM MALE GAMETE PROTEIN TO BLOCK MALARIA PARASITE TRANSMISSION
#51IMMUNOGENIC PEPTIDES, COMPOSITIONS, AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF MALARIA
#52Anti-PfRH5 antibodies and antigen-binding fragments thereof
#53Adenoviral Vectors Comprising Partial Deletions of E3
#54Vaccine for falciparum malaria
#55Compositions and methods of enhancing immune responses
#56IMMUNOSTIMULATORY COMPOSITIONS COMPRISING SOLUBLE PARASITE EXTRACTS AND USES THEREOF
#57PRE-ERYTHROCYTIC MALARIA VACCINES
#58Automated heart valve manufacturing
#59RECOMBINANT MEASLES VIRUS EXPRESSING PROTEINS OF A PLASMODIUM PARASITE AND THEIR APPLICATIONS
#60VACCINE IMMUNOGENS
#61ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME
#62MALARIA TRANSMISSION-BLOCKING VACCINES
#63Malaria immunogen and methods for using same
#64COMPOSITIONS OF ALUM NANOPARTICLES FOR IMMUNOMODULATION AND METHODS FOR PRODUCING THE SAME
#65BIOFUSION PROTEINS AS ANTI-MALARIA VACCINES
#66Compositions and methods for generating an immune response to treat or prevent malaria
#67MODIFIED VIRUS-LIKE PARTICLES OF CMV
#68Vaccines against malaria transmission
#69Compositions and methods of enhancing immune responses to or limiting infection
#70Circumsporozoite proteins with increased expression in mammalian cells
#71Compositions and methods of enhancing immune responses
#72TROPICAL DISEASE VACCINES
#73Infectious sporozoites grown in vitro
#74ANTI-NEOPLASTIC COMBINED PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
#75Automated heart valve manufacturing devices and methods
#76GLYCOPEPTIDE VACCINE
#77TREATMENT AND PREVENTION OF MALARIA
#78Vaccines
#79recombinanr xiexumapoeozoite protein compositions and method for vaccine delivery
#80ANTI-MALARIA COMPOSITIONS AND METHODS
#81MALARIA ANTIGENS ON THE SURFACE OF ERYTHROCYTES AND MEROZOITES AND PROTECTIVE ANTIBODIES
#82LONG CHAIN ANTIGEN CONTAINING INTEREPITOPE SEQUENCE THAT PROMOTES ANTIGEN PRESENTATION TO T CELLS
#83RNA FOR MALARIA VACCINES
#84Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine
#85Doubly attenuated late liver stage malaria parasites and related compositions and methods
#86INJECTABLE HYDROGELS FOR CONTROLLED RELEASE OF IMMUNOMODULATORY COMPOUNDS
#87PREDICTIVE BIOMARKERS FOR AN IMMUNE RESPONSE
#88VIRAL-VECTORED VACCINE FOR MALARIA
#89Covalently fused viral coat proteins for the display of target molecules
#90ADJUVANT EFFECT OF THE TLR1/2 AGONIST DIPROVOCIM SYNERGIZES WITH CHECKPOINT-INHIBITING ANTIBODIES TO ELIMINATE DISEASE
#91Immunogenic compositions, antigen screening methods, and methods of generating immune responses
#92BACTERICIDAL/PERMEABILITY INCREASING PROTEIN FOR USE IN A METHOD OF IMMUNIZATION, PREFERABLY AS AN ADJUVANT IN A METHOD OF VACCINATION
#93Malaria transmission blocking vaccine
#94Anti-parasitic immunological compositions
#95Vaccine for falciparum malaria
#96MALARIA VACCINE AND METHODS FOR PRODUCING SAME
#97SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES
#98Methods and Compositions for Vaccinating Against Malaria
#99COMPOSITIONS AND METHODS COMPRISING MEASLES VIRUS DEFECTIVE INTERFERING PARTICLES FOR THE PREVENTION OF INFECTIOUS DISEASES
#100Targeted vaccination in the liver
#101NON-PSYCHOACTIVE CANNABINOIDS AS ADJUVANTS TO ENHANCE MUCOSAL IMMUNITY
#102ARTHROSPIRA PLATENSIS ORAL VACCINE DELIVERY PLATFORM
#103VACCINES WITH INTERLEUKIN-33 AS AN ADJUVANT
#104Malaria pre-erythrocytic antigens as a fusion polypeptide and their use in the elicitation of a protective immune response in a host
#105Attenuation system and use thereof
#106Vaccines against malaria transmission
#107ENHANCEMENT OF PATHOGEN IMMUNOGENICITY
#108Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#109BIOFUSION PROTEINS AS ANTI-MALARIA VACCINES
#110USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORS
#111Anti-PfRH5 antibodies and antigen-binding fragments thereof
#112Adenoviral vectors comprising partial deletions of E3
#113Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
#114PD-1 Peptide Inhibitors
#115PD-1 peptide inhibitors
#116Dried composition of saponin in a liposomal formulation with a neutral lipid, a sterol, and a cryoprotectant
#117Tobamovirus-based virus-like particles and vaccines
#118MALARIAL VACCINATION METHODS AND REGIMENS
#119D-glycero-B-D-heptose 1-phosphate (HMP) conjugates and use for targeted immune modulation
#120Methods for inducing an immune response
#121Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
#122Composition, A Treatment Method and An Application Thereof
#123Chikungunya virus RNA vaccines
#124Zika virus RNA vaccines
#125Composition comprising an antigen and a substituted imidazo[1,2-a]pyrimidine for enhancing human immune response
#126Compositions and methods for generating an immune response to treat or prevent malaria
#127LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
#128and vaccine
#129Covalently fused viral coat proteins for the display of target molecules
#130Nanoparticle platform for antibody and vaccine delivery
#131VIRUS LIKE PARTICLE WITH EFFICIENT EPITOPE DISPLAY
#132Modified virus-like particles of CMV
#133NYVAC-based plasmodium malaria vaccine
#134Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host
#135Functional screening of antigenic polypeptides-use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity
#136PLASMODIUM FALCIPARUM AND PLASMODIUM VIVAX VACCINE
#137Infectious plasmodium sporozoites grown in vitro
#138ANTI-MALARIA COMPOSITIONS AND METHODS
#139Poxvirus-recombinants, compositions containing such recombinants, uses thereof, and methods of making and using the same
#140Subunit vaccine delivery platform for robust humoral and cellular immune responses
#141PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO
#142IMMUNOGENS OBTAINED FROM PLASMODIUM YOELII USING QUANTITATIVE SEQUENCELINKAGE GROUP SELECTION METHOD
#143SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDS
#144Immunomodulatory compositions and methods of use thereof
#145Malaria vaccine and methods for producing same
#146Vaccine for falciparum malaria
#147Doubly attenuated late liver stage malaria parasites and related compositions and methods
#148THERMOSTABLE VARIANTS OF P. FALCIPARUM PFRH5 WHICH CAN BE PRODUCED IN BACTERIAL CELLS
#149Adenoviral vectors comprising partial deletions of E3
#150MALARIA VACCINE
#151Malaria vaccine
#152Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
#153Compositions and methods of enhancing immune responses to or limiting infection
#154Plasmodium with histamine releasing factor (HRF) deficiency for use as a vaccine
#155COMPOSITIONS COMPRISING CelTOS IMMUNOGENS AND ANTIBODIES AND METHOD OF USE THEREOF
#156Malaria antigens and methods of use
#157Vaccine comprising drug and parasite administration
#158Hybrid hepadnavirus cores carrying multiple malaria parasite epitopes
#159Vaccines
#160Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
#161IDENTIFICATION AND PRODUCTION OF HIGH AFFINITY IGM ANTIBODIES AND DERIVATIVES THEREOF
#162Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#163Prime target
#164Antigen for use in malaria
#165Adenovirus based malaria vaccine encoding and displaying a malaria antigen
#166CROSS-REGULATION OF TYPE I INTERFERON SIGNALING PATHWAYS
#167Virus like particle with efficient epitope display
#168Long chain antigen containing interepitope sequence that promotes antigen presentation to T cells
#169Chikungunya virus RNA vaccines
#170Zika virus RNA vaccines
#171Anti-malarial compositions
#172Vaccines with interleukin-33 as an adjuvant
#173Dried saponin liposomal composition
#174Malaria antigens and methods of use
#175NEW ADJUVANT AND VACCINE COMPOSITION CONTAINING THE SAME
#176Polymer conjugate vaccines
#177METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION
#178METHODS FOR GENERATING NEUTRALIZING ANTI-PATHOGEN ANTIBODIES BY DIRECTING THE HUMORAL RESPONSE TOWARD DESIRED EPITOPES
#179Universal cancer vaccine
#180Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines
#181Anti-malaria compositions and methods
#182Immunogenic compositions, antigen screening methods, and methods of generating immune responses
#183PD-1 peptide inhibitors
#184IMMUNOGENIC COMPOSITIONS AND EXPRESSION SYSTEMS
#185PD-1 peptide inhibitors
#186Compositions and methods of enhancing immune responses to or limiting infection
#187Infectious plasmodium sporozoites grown in vitro
#188EXTENDED PROTECTION PROTEIN VACCINES AGAINST INFECTIOUS AGENTS
#189Malaria antigens and methods of use
#190ISG15 and its use as an adjuvant
#191PD-1 Peptide Inhibitors
#192Subunit vaccine delivery platform for robust humoral and cellular immune responses
#193COMPOSITION AND USES THEREOF
#194METHODS FOR MAKING ARRAYS FOR HIGH THROUGHPUT PROTEOMICS
#195Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#196Chikagunya virus RNA vaccines
#197Mosquito saliva protein malaria vaccine
#198MODIFICATION OF RECOMBINANT ADENOVIRUS WITH IMMUNOGENIC PLASMODIUM CIRCUMSPOROZOITE PROTEIN EPITOPES
#199Zika virus RNA vaccines
#200Vaccine for falciparum malaria
#201Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
#202Modified virus-like particles of CMV
#203Artificial antigen produced using partial sequence of enolase protein originated from plasmodium falciparum, and method for producing same
#204Purified plasmodium and vaccine compositions
#205Vaccine for malaria
#206Three-component-multistage malaria vaccine
#207Genetic attenuation of plasmodium by B9 gene disruption
#208Antigen for use in malaria
#209MALARIA ANTIGEN SCREENING METHOD
#210Polymer-protein core-shell particles as effective vaccine delivery vehicles and treatments methods using the same
#211Treatment and prevention of malaria
#212Method and compositions
#213Methods and compositions for transgene expression in a herpesvirus vector system
#214Methods for inducing an immune response
#215Anti-malaria compositions and methods
#216Methods for inducing an immune response
#217Multi-component-multistage malaria vaccines
#218Uses of parasite macrophage migration inhibitory factors
#219MALARIAL ANTIGENS DERIVED FROM SUBTILISIN-LIKE PROTEASE 2 AND VACCINES AND METHODS OF USE
#220IMMUNOGENIC COMPOSITIONS AND EXPRESSION SYSTEMS
#221Compositions and methods for immunodominant antigens
#222Malaria vaccines based on pre-erythrocytic antigens from
#223Vaccine compositions comprising a saponin adjuvant
#224Plasmodium falciparum antigens
#225Lipid vesicle compositions and methods of use
#226MALARIA VACCINE
#227Compositions and methods for immunodominant antigens of
#228Peptide/β-1,3-glucan complex and production method thereof and pharmaceutical composition containing peptide/β-1,3-glucan complex
#229Flagellin-containing protein nanoparticles as a vaccine platform
#230SERUM ANTIBODY ASSAY FOR DETERMINING PROTECTION FROM MALARIA, AND PRE-ERYTHROCYTIC SUBUNIT VACCINES
#231Immunomodulatory compositions and methods of use thereof
#232MOLECULAR ADJUVANT
#233Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction
#234Infectious plasmodium sporozoites grown in vitro
#235AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
#236Subunit vaccine platform based on multimeric ribonucleoproteins comprising nucleoproteins of a non-segmented negative-strand RNA virus as carriers of heterologous polypeptides
#237MALARIA VACCINATION
#238Vaccines with interleukin-33 as an adjuvant
#239Malaria vaccine
#240SERUM ANTIBODY ASSAY FOR DETERMINING PROTECTION FROM MALARIA, AND PRE-ERYTHROCYTIC SUBUNIT VACCINES
#241Virus like particle comprising modified envelope protein E3
#242Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions
#243Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
#244Anti-malarial compositions
#245Purified plasmodium and vaccine compositions
#246Antigenic compositions and methods
#247Pharmaceutical compositions comprising attenuated sporozoites and glycolipid adjuvants
#248Vaccine comprising AMA1 and RON2
#249Composition and uses thereof
#250Vaccines against pregnancy-associated malaria
#251Treatment and prevention of malaria
#252Phospholipid drug analogs
#253Vaccines against apicomplexan pathogens
#254Plasmodium falciparum antigens
#255Methods and compositions related to immunogenic fibrils
#256Virus like particle comprising modified envelope protein E3
#257Soluble recombinant plasmodium falciparum circumsporozoite protein, use in vaccines, methods of making and uses thereof
#258Lipid vesicle compositions and methods of use
#259Recombinantly expressed plasmodium CelTOS antigen and methods of use thereof
#260Vaccines having an antigen and interleukin-23 as an adjuvant
#261Rodent hepadnavirus cores with reduced carrier-specific antigenicity
#262Compositions and methods of enhancing immune responses to or limiting infection
#263Lentiviral vector based immunological compounds against malaria
#264Treatment and prevention of malaria
#265METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION
#266Purified plasmodium and vaccine compositions
#267Genetic attenuation of by B9 gene disruption
#268Adenovirus vectors
#269Malaria antigens and methods of use
#270sporozoite and liver stage antigens
#271USE OF P47 FROM PLASMODIUM FALCIPARUM (PFS47) OR PLASMODIUM VIVAX (PVS47) AS A VACCINE OR DRUG SCREENING TARGETS FOR THE INHIBITION OF HUMAN MALARIA TRANSMISSION
#272NOVEL MALARIA TRANSMISSION-BLOCKING VACCINES
#273Compositions and methods for immunodominant antigens of
#274POLYSACCHARIDE COMPOSITIONS AND METHODS OF USE
#275Anti-malarial compositions
#276ADENOVIRAL VECTOR-BASED MALARIA VACCINE
#277Conformation-stabilized TRAP antigens
#278Recombinant polypeptide construct comprising circumsporozoite protein HLA class I restricted T-cell epitopes
#279Methods and Compositions for Preventing a Condition
#280antigens
#281Rodent parasites as platforms for a whole-organism malaria vaccine
#282Combined measles-malaria vaccine
#283Subunit vaccine delivery platform for robust humoral and cellular immune responses
#284Malaria vaccine
#285Antigenic compositions and methods
#286Adjuvant formulations comprising TLR4 agonists and methods of using the same
#287Targeting of chondroitin sulfate glycans
#288Malaria vaccine
#289IMMUNOGENIC PLASMODIUM FALCIPARUM ANTIGEN COMPOSITIONS AND USES THEREOF
#290Vaccine for malaria
#291Adenoviral vector-based malaria vaccines
#292Malaria vaccine
#293Algal produced malarial transmission blocking vaccines
#294Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#295MODIFIED CATIONIC LIPOSOME ADJUVANTS
#296Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
#297Blood stage malaria vaccine
#298Production of a cysteine rich protein
#299ATTENUATED PLASMODIUM WITH DEACTIVATED HMGB2 GENE, AS VACCINE
#300Viral Vector Immunogenic Compositions